About SpyBiotech
SpyBiotech is a company based in Oxford (United Kingdom) founded in 2017 by Simon Draper and Sumi Biswas. SpyBiotech has raised $38.6 million across 3 funding rounds from investors including Gates Foundation, Oxford Investment Consultants and Google Ventures. The company has 10 employees as of March 31, 2021. SpyBiotech offers products and services including SPYVLP01 Vaccine and Protein Superglue Technology. SpyBiotech operates in a competitive market with competitors including Brii Biosciences, Insmed, Affinivax, Neon Therapeutics and Eligo Bioscience, among others.
- Headquarter Oxford, United Kingdom
- Employees 10 as on 31 Mar, 2021
- Founders Simon Draper, Sumi Biswas
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Spybiotech Limited
- Date of Incorporation 02 Mar, 2017
- Jurisdiction OXFORD, UNITED KINGDOM
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$38.6 M (USD)
in 3 rounds
-
Latest Funding Round
$4.09 M (USD), Grant
Mar 20, 2023
-
Investors
Gates Foundation
& 5 more
-
Employee Count
10
as on Mar 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SpyBiotech
SpyBiotech offers a comprehensive portfolio of products and services, including SPYVLP01 Vaccine and Protein Superglue Technology.
Targets Human Cytomegalovirus for disease prevention
Enables development of vaccines against multiple pathogens
People of SpyBiotech
Unlock access to complete
Unlock access to complete
Funding Insights of SpyBiotech
SpyBiotech has successfully raised a total of $38.6M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $4.09 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $4.1M
-
First Round
First Round
(10 Mar 2017)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2023 | Amount | Grant - SpyBiotech | Valuation |
investors |
|
| Feb, 2021 | Amount | Series A - SpyBiotech | Valuation | Braavos | |
| Mar, 2017 | Amount | Series A - SpyBiotech | Valuation | Oxford Science Enterprises |
Investors in SpyBiotech
SpyBiotech has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Oxford Investment Consultants and Google Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate backed venture capital fund investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Investment management services for science ventures are provided in Oxford.
|
Founded Year | Domain | Location | |
|
Braavos is associated with multiple companies.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SpyBiotech
Financial Statements - SpyBiotech
Spybiotech Comparisons
Competitors of SpyBiotech
SpyBiotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Brii Biosciences, Insmed, Affinivax, Neon Therapeutics and Eligo Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of biologics to treat hepatitis B infection
|
|
| domain | founded_year | HQ Location |
Developer of small molecule inhibitors for rare lung diseases
|
|
| domain | founded_year | HQ Location |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Tumor-specific neoantigens are identified for personalized cancer vaccine development.
|
|
| domain | founded_year | HQ Location |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| domain | founded_year | HQ Location |
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
|
Frequently Asked Questions about SpyBiotech
SpyBiotech was founded in 2017.
SpyBiotech is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Sumi Biswas is the current CEO of SpyBiotech. They have also founded this company.
SpyBiotech is a funded company, having raised a total of $38.6M across 3 funding rounds to date. The company's 1st funding round was a Series A of $6.1M, raised on Mar 10, 2017.
As of Mar 31, 2021, the latest employee count at SpyBiotech is 10.
SpyBiotech was founded in 2017 as a spinoff from Oxford University in the United Kingdom. Operations center on the biotechnology sector, where vaccines targeting bacterial infections are created through proprietary SpyTag and SpyCatcher components. These elements enable the production of virus-like particle vaccines. The company is headquartered in Oxford and focuses on advancing therapeutic options in this field.
SpyBiotech's top competitors include Brii Biosciences, Insmed and Osivax.
SpyBiotech offers SPYVLP01 Vaccine and Protein Superglue Technology.
SpyBiotech has 6 investors. Key investors include Gates Foundation, Oxford Investment Consultants, Google Ventures, Oxford Science Enterprises, and Braavos.
The valuation of SpyBiotech is $9.73M as of Mar 2017.